CDC42 and intestinal cancer: There are no mutations reported in the Cdc42 itself, but inhibition of Cdc42 leads to regression of tumors in intestinal cancers which harbour mutations in APC/β-Catenin [64], but there is no direct evidence for its involvement in CSC maintenance.